On October 7, 2026, the FDA approved Rhapsido (remibrutinib) for adults with symptomatic dermographism whose symptoms remain inadequately controlled with H1 antihistamines. As an allergist, I consider this an important development because symptomatic dermographism has historically had remarkably few treatment options.
Symptomatic dermographism is a form of chronic inducible urticaria in which scratching, rubbing, pressure from clothing, or other minor friction can produce raised, intensely itchy hives. While mild “skin writing” can occur without causing meaningful problems, patients with symptomatic disease may experience itching, burning, sleep disturbance, and significant interference with daily activities.
Treatment has traditionally centered on second-generation H1 antihistamines, sometimes increased above standard dosing under physician supervision. For patients who remain uncontrolled, omalizumab (Xolair) has substantial clinical experience and evidence, although its use for symptomatic dermographism has been off-label.
Remibrutinib changes that landscape. It is an oral Bruton’s tyrosine kinase (BTK) inhibitor that interferes with intracellular signaling involved in mast-cell activation and histamine release. In the Phase 3 RemIND trial, 29.3% of patients receiving remibrutinib achieved complete hive response at Week 12 compared with 14.0% receiving placebo, with responses observed as early as Week 2.
What makes this approval especially significant is that it recognizes symptomatic dermographism as a disease deserving therapies studied specifically for it—not simply as a variation of “hives.”
The treatment landscape may continue to expand. One particularly interesting investigational therapy is barzolvolimab, an anti-KIT monoclonal antibody designed to reduce mast-cell activity and numbers. Clinical studies have demonstrated promising responses in symptomatic dermographism, and Phase 3 development is underway. Researchers are also studying newer approaches targeting mast-cell pathways such as MRGPRX2, which could eventually provide additional oral treatment strategies.
For allergists, the larger story is the rapid evolution of chronic urticaria treatment. We are moving beyond simply blocking histamine after mast cells release it and toward therapies that intervene earlier in the mast-cell signaling pathway itself. For patients with severe symptomatic dermographism who continue to develop hives from everyday friction despite antihistamines, the FDA approval of Rhapsido represents a meaningful new option—and potentially the beginning of a much broader era of targeted treatment for chronic inducible urticaria.